

export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Biogen, Inc., Fourteen Cambridge Center, Cambridge, MA 02142, has filed an application requesting approval for the export of the human biological product AVONEX™, Recombinant Interferon Beta-1a to the United Kingdom. AVONEX™, Recombinant Interferon Beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis. The application was received and filed in the Center for Biologics Evaluation and Research on October 2, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by November 6, 1995, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Biologics Evaluation and Research (21 CFR 5.44).

Dated: October 13, 1995.

James C. Simmons,

Director, Office of Compliance, Center for Biologics Evaluation and Research.

[FR Doc. 95-26632 Filed 10-26-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 93N-0046]

Westmar Oceanside, Inc.; Revocation of U.S. License No. 828

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the revocation of the establishment license (U.S. License No. 828) and the product license issued to Westmar Oceanside, Inc., for the manufacture of Source Plasma. A notice of opportunity for a hearing on a proposal to revoke the licenses was published in the Federal Register of May 6, 1993. In a letter to FDA dated June 1, 1993, a representative of Westmar Oceanside, Inc., indicated that the firm was no longer in business and requested voluntary revocation of the establishment license and product license and thereby waived an opportunity for a hearing.

DATES: The revocation of the establishment license (U.S. License No. 1082) and product license became effective August 3, 1993.

FOR FURTHER INFORMATION CONTACT: Stephen M. Ripley, Center for Biologics Evaluation and Research (HFM-635), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-594-3074.

SUPPLEMENTARY INFORMATION: FDA has revoked the establishment license (U.S. License No. 828) and the product license issued to Westmar Oceanside, Inc., 1024 South Hill St., Oceanside, CA 92504, for the manufacture of Source Plasma.

By letter dated December 11, 1991, FDA advised Westmar Oceanside, Inc., that FDA intended to initiate proceedings to revoke the establishment and product licenses. In the Federal Register of May 6, 1993 (58 FR 26982), FDA published a notice of opportunity for a hearing on the proposed revocation of the licenses pursuant to 21 CFR 12.21(b), as provided in 21 CFR 601.5(b). As described in the notice of opportunity for a hearing, the grounds for the proposed license revocation included the following: (1) The results of the FDA inspection of Westmar Oceanside, Inc., conducted in August through September 1991; (2) the results of an FDA investigation of Westmar Oceanside, Inc., conducted concurrently with the August/September 1991 inspection; (3) a determination by FDA that the deviations documented during the August/September 1991 inspection and investigation showed serious noncompliance with the applicable

biologics regulations and standards of the firm's license; and (4) a determination by FDA that the violations at the firm were significant and willful. Documentation in support of the proposed revocation had been placed on file for public examination with the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

The notice of opportunity for a hearing provided 30 days for Westmar Oceanside, Inc., to submit a written request for a hearing, as specified in 21 CFR 12.21(b), and 60 days to submit any data or information justifying a hearing. The notice of opportunity for a hearing provided 60 days for other interested persons to submit written comments on the proposed revocation action. A representative for Westmar Oceanside, Inc., responded to the notice of opportunity for a hearing by letter dated June 1, 1993. The letter stated that the firm was no longer in business and requested voluntary revocation of the firm's establishment license and product license and thereby waived an opportunity for a hearing. In a letter dated August 3, 1993, to the firm, FDA revoked the establishment license (U.S. License No. 828) and the product license issued to Westmar Oceanside, Inc.

No other written comments on the proposed revocation were received within the prescribed 60 days specified in the notice of opportunity for a hearing.

FDA has placed a copy of FDA's August 3, 1993, letter on file with the Dockets Management Branch (address above) under the docket number found in brackets in the heading of this notice. This document is available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Accordingly, under 21 CFR 601.5, section 351 of the Public Health Service Act (42 U.S.C. 262), and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Biologics Evaluation and Research (21 CFR 5.68), the establishment license (U.S. License No. 828) and the product license issued to Westmar Oceanside, Inc., for the manufacture of Source Plasma were revoked, effective August 3, 1993.

This notice issued and published under 21 CFR 601.8 and the redelegation at 21 CFR 5.67.

Dated: October 17, 1995.

Kathryn C. Zoon,

Director, Center for Biologics Evaluation and Research.

[FR Doc. 95-26631 Filed 10-26-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 95N-0194]

The Dr. Oscar E. Carter, Jr., Memorial Rehabilitation Center, Inc.; Proposal to Revoke Approval of a Narcotic Addiction Treatment Program; Opportunity for a Hearing; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of August 11, 1995 (60 FR 41079). The document proposed to revoke approval of an "Application for Approval of Use of Methadone in a Treatment Program" (Form FDA-2632) (renamed "Application for Approval for Use of Narcotic Drugs in a Treatment Program") held by The Dr. Oscar E. Carter, Jr., Memorial Rehabilitation Center, Inc. (Carter). The document was published with an incorrect docket number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Gerald R. Hajarian, Center for Drug Evaluation and Research (HFD-342), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1029.

In FR Doc. 95-19885, appearing on page 41079 in the Federal Register of Friday, August 11, 1995, the following corrections are made:

1. On page 41079, in the 2d column, in the 1st line of the document, and in the 3d column, in the "ADDRESSES" section, in the 4th line, the docket number "95N-0193" is corrected to read "95N-0194".

Dated: October 23, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95-26737 Filed 10-26-95; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Community Planning and Development

[Docket No. FR-3778-N-60]

Federal Property Suitable as Facilities To Assist the Homeless

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

EFFECTIVE DATE: October 27, 1995.

FOR FURTHER INFORMATION CONTACT: Mark Johnston, Department of Housing and Urban Development, Room 7256, 451 Seventh Street SW, Washington, DC 20410; telephone (202) 708-1226; TDD number for the hearing- and speech-impaired (202) 708-2565, (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1-800-927-7588.

SUPPLEMENTARY INFORMATION: In accordance with the December 12, 1988 court order in *National Coalition for the Homeless v. Veterans Administration*, No. 88-2503-OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist the homeless. Today's Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week.

Dated: October 20, 1995.

Jacque M. Lawing,

Deputy Assistant Secretary for Economic Development.

[FR Doc. 95-26550 Filed 10-26-95; 8:45 am]

BILLING CODE 4210-29-M

Office of the Assistant Secretary for Housing—Federal Housing Commissioner

[Docket No. FR-3907-N-02]

Housing Counseling Program: Announcement of Funding Awards for FY 1995

AGENCY: Office of the Assistant Secretary for Housing—Federal Housing Commissioner, HUD.

ACTION: Announcement of Housing Counseling Funding Awards.

SUMMARY: In accordance with section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this announcement notifies the public of funding award decisions made by the Department under its Housing Counseling Program for Fiscal Year 1995. The announcement contains the names and addresses of the award winners and the amount of the awards.

FOR FURTHER INFORMATION CONTACT: Marion F. Connell, Program Advisor, Office of Housing, Department of Housing and Urban Development, Room 9282, 451 Seventh Street, SW, Washington, DC 20410, telephone (202) 708-0614, extension 2315 (voice) or (202) 708-4594 (TDD). (These are not toll-free numbers.)

SUPPLEMENTARY INFORMATION: HUD's housing counseling program is authorized under section 106 of the Housing and Urban Development Act of 1968 (12 U.S.C. 1701x). The purpose of the program is to promote and protect the interests of housing consumers participating in HUD and other housing programs, as well as to help protect the interests of HUD and mortgage lenders. Under the housing counseling program, HUD contracts with pre-qualified public or private nonprofit organizations to provide the services authorized by the statute. These organizations are referred to as "HUD approved housing counseling agencies". When Congress makes funds available for this purpose, HUD announces the availability of such funds, and invites applications from eligible agencies, through a notice of funding availability (NOFA) published in the Federal Register.

In a Notice of Funding Availability (NOFA) published on May 24, 1995 (60 FR 27538), HUD announced the availability of \$9.5 million to provide Housing Counseling Grants in accordance with Section 106: (1) \$3.5 million to help fund national, regional and multi-State HUD approved housing counseling intermediary organizations, and, (2) \$6 million to help fund local HUD approved counseling agencies.

In accordance with section 102 (a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, the Department is publishing (by State) the names and addresses of the HUD-approved agencies awarded funds under the FY 1995 Housing Counseling NOFA, and the amount of funds awarded to each agency. This information is provided in Appendix A to this document.